{
  "docId": "019de073-3cb6-7521-8cc2-fe64231d84c9",
  "docSlug": "d538949ee3add2afed287b359e626655",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 25 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 25,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a split-layout with company mission on the left and product details on the right.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/5",
  "deckHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9",
  "deckJsonHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json",
  "deckAnchorHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.3,
        "y": 0.82
      },
      "kind": "callout",
      "text": "We expect our boron chemistry expertise to drive future pipeline of differentiated compounds",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06122da7-2bdf-477a-8335-637dd21de042",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.65,
        "x": 0.3,
        "y": 0.1
      },
      "kind": "list",
      "text": "Epetraborole (EBO): Pivotal phase 2/3 ready antibiotic product candidate for non-tuberculous mycobacterial (NTM) lung disease",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f293b2d-5542-4097-8847-21ea3222bb2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.3,
        "y": 0.75
      },
      "kind": "list",
      "text": "Potential to develop epetraborole to address additional geographies and NTM indications",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "779cce92-06d8-4a98-93e8-81e2fe0c4c23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.3,
        "y": 0.2
      },
      "kind": "list",
      "text": "Large market opportunity given the high unmet need; Arikayce, the only approved therapy for NTM lung disease, had 2021 WW net sales of >$189M in its third year on the market (Arikayce 2Q'22: WW $65.2M +44% Y/Y)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e067aba-4071-4a98-8b02-eb45a0db13b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.3,
        "y": 0.6
      },
      "kind": "list",
      "text": "Phase 2/3 pivotal trial expected to support U.S. and Japan regulatory approval for treatment-refractory MAC lung disease; initiated study June 2022; topline Phase 2 data mid 2023; QIDP, Fast Track, and orphan drug designations granted in U.S.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c84898c9-8d03-4614-ab69-bb56c91b21a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.3,
        "y": 0.35
      },
      "kind": "list",
      "text": "Ideal Target Product Profile: Novel mechanism of action, broad spectrum antimycobacterial activity; Convenient, once-daily oral dosing; Superior profile compared to SoC combination regimen in preclinical NTM models; Multiple Phase 1 studies out to 28 days of dosing support well-tolerated dose and high probability of target attainment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea34f056-2231-41cb-99de-7c0ef4de2897",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "paragraph",
      "text": "AN2 Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54893bff-cd5a-45c8-b131-911a271a8a65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.3,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "1. Insmed FY 2021 10-K 2. Insmed 2Q 2022 10-Q",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86a81d83-7352-4ec1-807b-420c1dd22df8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}